| PEGylated chitosan for nonviral aerosol and mucosal delivery of the CRISPR/Cas9 system in vitro H Zhang, TF Bahamondez-Canas, Y Zhang, J Leal, HDC Smyth Molecular pharmaceutics 15 (11), 4814-4826, 2018 | 67 | 2018 |
| Effective dystrophin restoration by a novel muscle-homing peptide–morpholino conjugate in dystrophin-deficient mdx mice X Gao, J Zhao, G Han, Y Zhang, X Dong, L Cao, Q Wang, HM Moulton, ... Molecular Therapy 22 (7), 1333-1341, 2014 | 66 | 2014 |
| Caveolin-1–derived peptide limits development of pulmonary fibrosis AS Marudamuthu, YP Bhandary, L Fan, V Radhakrishnan, BA MacKenzie, ... Science translational medicine 11 (522), eaat2848, 2019 | 65 | 2019 |
| Manufacturing and ambient stability of shelf freeze dried bacteriophage powder formulations Y Zhang, X Peng, H Zhang, AB Watts, D Ghosh International journal of pharmaceutics 542 (1-2), 1-7, 2018 | 56 | 2018 |
| Just how prevalent are peptide therapeutic products? A critical review Y Zhang, H Zhang, D Ghosh, RO Williams III International journal of pharmaceutics 587, 119491, 2020 | 38 | 2020 |
| Novel formulations and drug delivery systems to administer biological solids Y Zhang, DA Davis, K AboulFotouh, J Wang, D Williams, A Bhambhani, ... Advanced drug delivery reviews 172, 183-210, 2021 | 33 | 2021 |
| The stabilizing excipients in dry state therapeutic phage formulations Y Zhang, H Zhang, D Ghosh AAPS PharmSciTech 21, 1-14, 2020 | 28 | 2020 |
| A repurposed drug for brain cancer: Enhanced atovaquone amorphous solid dispersion by combining a spontaneously emulsifying component with a polymer carrier H Takabe, ZN Warnken, Y Zhang, DA Davis, HDC Smyth, JG Kuhn, ... Pharmaceutics 10 (2), 60, 2018 | 25 | 2018 |
| Development of an excipient-free peptide dry powder inhalation for the treatment of pulmonary fibrosis Y Zhang, BA MacKenzie, JJ Koleng, E Maier, ZN Warnken, RO Williams III Molecular pharmaceutics 17 (2), 632-644, 2020 | 23 | 2020 |
| Formulation strategies in immunotherapeutic pharmaceutical products Y Zhang, RO Williams III, HO Tucker World Journal of Clinical Oncology 11 (5), 275, 2020 | 10 | 2020 |
| Manufacturing stable bacteriophage powders by including buffer system in formulations and using thin film freeze-drying technology Y Zhang, M Soto, D Ghosh, RO Williams Pharmaceutical Research 38, 1793-1804, 2021 | 9 | 2021 |
| Development of PEGylated chitosan/CRISPR-Cas9 dry powders for pulmonary delivery via thin-film freeze-drying H Zhang, Y Zhang, RO Williams III, HDC Smyth International Journal of Pharmaceutics 605, 120831, 2021 | 9 | 2021 |
| Meeting report: Vaccine stability considerations to enable rapid development and deployment M Alasandro, D Choudhury, K Huynh-Ba, J Kochling, C Latoz, L Larkin, ... Aaps Open 7, 1-9, 2021 | 4 | 2021 |
| Biologically active dry powder compositions and method of their manufacture and use HDC Smyth, H Zhang, Z Cui, J Wang, XU Haiyue, Y Zhang, D Ghosh, ... US Patent App. 17/235,771, 2022 | 1 | 2022 |
Robert O. Williams IIIUniversity of Texas at AustinVerified email at austin.utexas.edu
